Drug Repurposing and Systems Biology approaches of Enzastaurin can target potential biomarkers and critical pathways in Colorectal Cancer

Colorectal cancer (CRC) is a severe health concern that results from a cocktail of genetic, epigenetic, and environmental abnormalities. Because it is the second most lethal malignancy in the world and the third-most common malignant tumor, but the treatment is unavailable. The goal of the current s...

Full description

Saved in:
Bibliographic Details
Published in:Computers in biology and medicine 2023-03, Vol.155, p.106630-106630, Article 106630
Main Authors: Somadder, Pratul Dipta, Hossain, Md Arju, Ahsan, Asif, Sultana, Tayeba, Soikot, Sadat Hossain, Rahman, Md Masuder, Ibrahim, Sobhy M., Ahmed, Kawsar, Bui, Francis M.
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
Abnormalities
Age
AKT protein
Apoptosis
Bioinformatics
Biology
Biomarkers
Biomarkers, Tumor - genetics
Cancer
Chemical compounds
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - pathology
Computational Biology - methods
Critical Pathways
Drug Repositioning
EGFR
Enzastaurin
Epigenetics
Gene expression
Genomes
Hub proteins
Humans
Kinases
Malignancy
Mcl-1 protein
MDS
Molecular docking
Molecular Docking Simulation
Molecular dynamics
Nucleus
Ontology
Pharmacokinetics
Pharmacology
Phosphatidylinositol 3-Kinases
Phosphorylation
PI3K-Akt
PPI
Protein interaction
Protein-tyrosine kinase
Proteins
Rap1 protein
Signal transduction
Signaling
Systems Biology
Therapeutic targets
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is a severe health concern that results from a cocktail of genetic, epigenetic, and environmental abnormalities. Because it is the second most lethal malignancy in the world and the third-most common malignant tumor, but the treatment is unavailable. The goal of the current study was to use bioinformatics and systems biology techniques to determine the pharmacological mechanism underlying putative important genes and linked pathways in early-onset CRC. Computer-aided methods were used to uncover similar biological targets and signaling pathways associated with CRC, along with bioinformatics and network pharmacology techniques to assess the effects of enzastaurin on CRC. The KEGG and gene ontology (GO) pathway analysis revealed several significant pathways including in positive regulation of protein phosphorylation, negative regulation of the apoptotic process, nucleus, nucleoplasm, protein tyrosine kinase activity, PI3K-Akt signaling pathway, pathways in cancer, focal adhesion, HIF-1 signaling pathway, and Rap1 signaling pathway. Later, the hub protein module identified from the protein-protein interactions (PPIs) network, molecular docking and molecular dynamics simulation represented that enzastaurin showed strong binding interaction with two hub proteins including CASP3 (−8.6 kcal/mol), and MCL1 (−8.6 kcal/mol), which were strongly implicated in CRC management than other the five hub proteins. Moreover, the pharmacokinetic features of enzastaurin revealed that it is an effective therapeutic agent with minimal adverse effects. Enzastaurin may inhibit the potential biological targets that are thought to be responsible for the advancement of CRC and this study suggests a potential novel therapeutic target for CRC. •Exploring pharmacological mechanisms of Enzastaurin to inhibit CRC progression as a novel therapeutic approach.•Identified genetic profiles, signaling, gene ontology, and protein interactome by using global transcriptomic data.•Important hub genes (EGFR, ERBB2, ATM, MCL1, VEGFA, AKT1, HSP90AA1, CASP3) could be targeted for therapeutic intervention.•Two potential biomarkers CASP3 (-8.6 Kcal/mol) and MCL1 (-8.6 Kcal/mol) with Enzastaurin used as inhibitors to manage CRC.•Then ADMET analysis was employed in computational drug discovery process as the most inexpensive approach.
ISSN:0010-4825
1879-0534
DOI:10.1016/j.compbiomed.2023.106630